|
| |
Double-Digit-Growing Cancer Therapeutics Market Could Top $89 Billion by 2011!
New York, February 15, 2007 — Expecting more than $11 billion in new
therapeutics to gain approval within the next four years, the global market for
cancer therapies is poised to surpass $89 billion in sales by 2011, according to
Cancer Therapeutics: The Worldwide Market, the latest findings from market
research firm Kalorama Information.
Forecast to display steady growth of more than 14% from 2006 to 2011, the market
reached sales in excess of $46 billion in 2006, increasing by more than 18% over
2004 sales. Led by strong performance in the immunotherapy segment, which
currently commands a slightly more than 31% market share, the market is also
being bolstered by the radiation therapy segment as well as by product growth in
several areas of the adjunctive therapies segment.
Innovation has been and will continue to be the key to growth. In 2006, 26
cancer therapies were approved in the U.S., the largest number in history. With
more than 50 therapies currently in Phase III or awaiting approval, the cancer
therapeutics is clearly the forerunner in drug development.
“Targeted cancer therapeutics are an exciting prospect that has the potential to
improve patient survival from serious malignancies. Similarly, the prospect of
combining new agents with older forms of therapy, such as small molecule
chemotherapy or hormonal therapy, also offers promise for improvement in disease
outcomes,” notes Melissa Elder, the report’s author. “At the same time, the
incorporation of molecular tools into contemporary drug development is mandatory
if the clinical impact of new anticancer agents is to be realized.”
This study examines the global market for therapies for a broad range of cancers
including: bladder, breast, cervical, colorectal, kidney, leukemia, liver, lung,
lymphoma, melanoma, multiple myeloma, ovarian, and prostate among others.
Therapy types covered in the report include chemotherapy, hormone and radiation
therapy, immunotherapy and biotherapy, and adjunctive therapies.
Cancer Therapeutics also includes extensive coverage of research and
development pipelines, in-depth company profiles, four-region geographic
breakdowns, over 160 tables and figures, and more.
About Kalorama Information
Kalorama Information, a division of MarketResearch, supplies the latest
in independent market research for the life sciences. To view their catalogue go
to:
http://www.bioportfolio.com/cgi-bin/acatalog/Kalorama.html
| |
|
